TNO155 is a selective SHP2 inhibitor to target PTPN11-dependent oral squamous cell carcinoma

TNO155 is a selective SHP2 inhibitor to target PTPN11-dependent oral squamous cell carcinoma

Oral squamous cell carcinoma (OSCC) is known to be driven by multiple intricated receptor tyrosine kinases (RTKs) including EGFR, PI3K/AKT and MAPK signaling pathways. However, whilst targeting EGFR with cetuximab has been approved for the treatment of OSCC, other single-agent inhibitors of the RTKs...

Full description

Bibliographic Details
Main Authors: Annie Wai Yeeng Chai, Yee Hua Tan, Shiyin Ooi, Pei San Yee, Shi Mun Yee, Sok Ching Cheong
Format: Article
Language:English
Published: Elsevier 2024-11-01
Series:Heliyon
Subjects:
RTK signaling
OSCC
Drug resistance
Essential genes
PTPN11
SHP2
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844024157088

Internet

http://www.sciencedirect.com/science/article/pii/S2405844024157088

Similar Items